Retrospective Study Based on Somatic Mutations, Genetic Polymorphisms and Metabolomics Related to Individual Variations of Drug Effect and Adverse Drug Reaction of EGFR-TKIs,Gefitinib and Erlotinib in Non-small Cell Lung Cancer Treatment.
Phase of Trial: Phase IV
Latest Information Update: 05 Sep 2019
Price : $35 *
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- 28 Aug 2019 Planned End Date changed from 1 Oct 2018 to 1 Dec 2021.
- 28 Aug 2019 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2021.
- 31 Aug 2018 Biomarkers information updated